Legacy Healthcare
Johanne Barthelet-Harti is a co-founder and board member at Legacy Healthcare with extensive experience in various managerial roles in companies such as TREMAIL Logistics SA, PwC, and Valtech. Johanne specializes in global freight forwarding, overseas logistics, transaction services, due diligence, and post-deal integration. Johanne also has a background in logistics and supply chain as a consultant at Valtech.
This person is not in any teams
Legacy Healthcare
Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile population, e.g. children, cancer patients and the elderly, who may be already on multiple medications. Our first drug, Coacillium, is currently in Phase II/III testing for the treatment of Alopecia Areata, a debilitating scalp condition with intense medical and psychological impact on all patients, especially in children, and their families. Coacillium’s safety profile is without equal. For this reason health authorities have taken the unusual step of authorizing testing in children (starting at age 2) before adult testing. We expect Coacillium to be approved by 2023, as the first drug for Pediatric Alopecia Areata.